The present invention relates to a crystal form of a potassium-competitive acid blocker, that is, 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-yl]-N-methyl methylamine fumaric acid salt (which is briefly referred to as a formula I) and a preparation method thereof. An X-ray powder diffraction characteristic peak thereof is shown in FIG. 1 . The crystal form that is represented by formula I, provided in the present invention, is stable, reproducible, and is suitable for drug development. [structure]

Description

10 parts

›CROSS-REFERENCE TO RELATED APPLICATION

This application is a Section 371 of International Application No. PCT/CN2015/094120, filed Nov. 9, 2015, which was published in the Chinese language on May 19, 2016, under International Publication No. WO 2016/074597 A1, and the disclosure of which is incorporated herein by reference.

›FIELD OF THE INVENTION

The present invention relates to the field of medicinal chemistry, and specifically relates to a crystal form of a potassium-competitive acid blocker, namely 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate, and a preparation method thereof.

›BACKGROUND OF THE INVENTION

1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate was developed by Takeda Pharmaceutical company, for use in treating an acid-related disease (e.g., duodenal ulcer, esophagitis, gastroesophageal reflux disease, eradicating Helicobacter pylori , peptic ulcer, gastric ulcer). 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate is a potassium-competitive acid blocker (P-CAB), which functions by competitively inhibiting potassium ions in the hydrogen ion/potassium ion-ATP enzyme. It is a reversible potassium antagonist, and belongs to a novel proton pump inhibitor. Its structural formula is as follows:

There are currently no reports of crystal forms of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate and preparation methods thereof.

›SUMMARY OF THE INVENTION

An objective of the present invention is to provide a novel crystal form of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate of formula I.

The crystal form can be identified by its characteristic X-ray powder diffraction (XRPD) spectrum.

The crystal form can be characterized by a characteristic X-ray powder diffraction (XRPD) spectrum, which comprises peaks at 2θ±0.2°: 12.30, 13.59, 15.34, 18.67, 20.48, 21.69, 25.23, 26.92°, wherein the X-ray powder diffraction spectrum is obtained by using CuK α1 radiation.

Particularly preferably, the characteristic XRPD peaks of the crystal form of the potassium-competitive acid blocker of the present invention are shown in the table below:

2θ (°)

5.24

11.51

11.76

12.30

13.59

14.02

15.34

16.22

16.96

17.48

17.92

18.67

19.20

20.48

20.85

21.69

22.53

23.10

23.59

24.50

25.23

25.65

26.21

26.92

27.80

28.91

30.46

30.68

32.83

33.92

34.92

36.21

Further preferably, the XRPD data of the crystal form is shown as follows:

Moreover, the crystal form of the compound of formula I can be characterized by a melting point of about 206° C.±3° C. (determined by DSC; evaluated by the starting temperature; with a heating rate of 10 K/minute). The DSC curve obtained is shown in FIG. 2 .

In order to allow experimental error, the aforementioned 2θ should be considered to be accurate to 2θ±0.20. In other words, when determining whether or not a crystal sample of a given compound A is the crystal form of the present invention, if the 2θ value of the sample observed in an experiment falls into the ±0.2° range of a 2θ characteristic value, then it should be considered to be the same as the aforementioned characteristic value.

In another aspect, the present invention relates to a method of preparing the crystal form of formula I, comprising the following steps of:

(a) dissolving 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate in a solvent or a mixture of solvents to form a saturated or nearly saturated solution;

(b) storing the solution in order to precipitate the crystal form from the solution, thereby forming a suspension;

(d) drying the precipitate to remove the solvent or the mixture of solvents.

Preferably, the solvent is selected from the group consisting of C 1-4 -alkanol, water, ethyl acetate, acetonitrile, acetone, methyl tert-butyl ether, N,N-dimethyl formamide, and a mixture of two or more of these solvents.

Preferably, step (a) is carried out at room temperature (about 20° C.) or at a rising temperature about below the boiling point of the solvent used or the mixture of solvents used.

Optionally, one or more poor solvents can be added in step (a) and/or step (b) to reduce the solubility of formula I in the solution.

Preferably, the temperature of the solution in step (b) can be room temperature (about 20° C.) or below.

Optionally, step (b) can be carried out with or without stirring.

Optionally, a seed crystal can be added or not added in step (b).

Preferably, in step (c), the precipitate can be separated by means using known methods, such as filtration, suction filtration, spin filtration, decantation or centrifugation.

Preferably, in step (d), the filtered solvent or the mixture of solvents can be removed under conditions of normal pressure or reduced pressure, heating or no heating.

Another objective of present invention is to provide a pharmaceutical composition comprising the crystal form.

The crystal form of the compound of formula I provided by the present invention is stable, reproducible, and suitable for drug development.

›BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the X-ray powder diffraction spectrum of the crystal form of the compound of formula I of the present invention; and

FIG. 2 shows the DSC spectrum of the crystal form of the compound of formula I.

›DETAILED DESCRIPTION OF THE INVENTION

In order to further illustrate the present invention, the present invention will be described in detail with reference to the specific examples below, but the scope of the present invention is not limited to these specific examples.

›Examples4

›EXAMPLE 1

2 g of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate were dissolved in 20 ml of a mixture of water/isopropanol (volume ratio 3:7), which had been heated to about 70° C. The solution was cooled to about 5° C. in 3 to 5 hours, stirred for 1 hour, and filtered under reduced pressure. The filter cake was dried at 50° C. for 8 hours to obtain 1.4 g of a crystal form. The XRPD spectrum and DSC spectrum of the crystal form are shown in FIGS. 1 and 2 , respectively.

›EXAMPLE 2

2 g of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate were dissolved in 80 ml of a mixture of ethyl acetate/methanol (volume ratio 1:7), which had been heated to about 70° C. The solution was cooled to about 5° C. in 3 to 5 hours, stirred for 1 hour, and filtered under reduced pressure. The filter cake was dried at 50° C. for 8 hours to obtain 1.2 g of a crystal form. The XRPD spectrum of the crystal form was substantially consistent with FIG. 1 , and the DSC spectrum of the crystal form is shown in FIG. 2 .

›EXAMPLE 3

2 g of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate were dissolved in 80 ml of methanol, which had been heated to about 65° C. The solution was cooled to about 5° C. in 3 to 5 hours, stirred for 1 hour, and filtered under reduced pressure. The filter cake was dried at 50° C. for 8 hours to obtain 1.0 g of a crystal form. The XRPD spectrum of the crystal form was substantially consistent with FIG. 1 , and the DSC spectrum of the crystal form is shown in FIG. 2 .

›EXAMPLE 4

2 g of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate were dissolved in 30 ml of water, which had been heated to about 95° C. The solution was cooled to about 5° C. in 3 to 5 hours, stirred for 1 hour, and filtered under reduced pressure. The filter cake was dried at 50° C. for 8 hours to obtain 1.5 g of a crystal form. The XRPD spectrum of the crystal form was substantially consistent with FIG. 1 , and the DSC spectrum of the crystal form is shown in FIG. 2 .

Experimental Example 1: Comparative Study on the Crystal Forms of Samples Before and after Stability Testing

The samples were prepared according to the method of Example 1, then were placed under the long-term stability conditions (temperature: 30° C.; humidity: 65%) for six months. The X-ray powder diffractions of the samples were then determined. The X-ray powder diffraction spectra were analyzed, and compared with the starting data. The comparison data are shown in Table 2:

Experimental Example 2: Comparative Study on the Crystal Forms Before and after Grinding

The samples were prepared according to the method of Example 1, and the following tests were carried out:

(1) directly grinding the sample for 5 minutes; and

(2) directly micronizing the samples.

The X-ray powder diffraction test was carried out on the aforementioned two samples respectively, and the data was compared with the starting data. The comparison data are shown in Table 3.

Experimental Example 3: Study on Hygroscopicity of Samples

The samples were prepared according to the method of Example 1, and the following tests were carried out:

(1) placing the sample at 25° C. and 75% humidity;

(2) placing the sample at 25° C. and 92.5% humidity.

The aforementioned two samples were taken and tested at different time points to investigate weight gain of the samples due to moisture absorption. The comparison data are shown in Table 4.

Experimental Example 4: Comparative Study on Samples Before and after Stability Testing

The samples were prepared according to the method of Example 1, and then were placed under the long-term stability conditions (temperature: 30° C.±2° C.; humidity: 65%±5%) for six months. The inspection items were tested, and the comparison data are shown in Table 5:

Experimental Example 5: Study on Dissolution of Tablets Prepared from Samples

Active pharmaceutical ingredient (API) tablets (conventional tabletting) were obtained from the samples prepared according to the method of Example 1. The dissolution rates of the samples were investigated in 0.1 mol/L HCl solution, acetate buffer pH 4.5, phosphate buffer pH 6.8 and purified water, respectively. The comparison data are shown in Table 6:

It can be seen from the stability inspection data of the samples that the crystal form of the present invention has good stability, and conforms to medicinal quality standards.

›Tables in the description — 5

TABLE 1 — X-ray powder diffraction data of the crystal form of the compound of formula I:

2θ (°)	d-value (Å)	Intensity I/I 0 (%)
5.24	16.847	7.3
11.51	7.684	34.3
11.76	7.521	39.5
12.30	7.188	70.1
13.59	6.512	100
14.02	6.312	19.1
15.34	5.770	96.5
16.22	5.460	13.7
16.96	5.224	37.0
17.48	5.069	45.5
17.92	4.945	17.7
18.67	4.749	88.9
19.20	4.620	9.4
20.48	4.333	92.4
20.85	4.256	36.7
21.69	4.094	69.4
22.53	3.943	24.3
23.10	3.847	31.0
23.59	3.768	6.2
24.50	3.630	12.4
25.23	3.528	96.7
25.65	3.471	34.7
26.21	3.398	13.6
26.92	3.310	76.0
27.80	3.207	30.4
28.91	3.086	5.3
30.46	2.932	12.4
30.68	2.912	18.8
32.83	2.726	7.6
33.92	2.640	10.5
34.92	2.567	15.2
36.21	2.479	9.7

TABLE 2 — Comparison of the X-ray powder diffraction data of the samples placed under long-term stability conditions For six months under long-term Conclusion: After comparing the aforementioned XRPD spectra, it was found that there were no obvious changes in d-values and 2θ angles of the diffraction peaks. After being placed under long-term stability conditions (temperature: 30° C.; humidity: 65%) for six months, the crystal forms of three batches of samples had not changed.

	At the beginning		stability conditions
Numbers	2θ (°)	d-value (Å)	2θ (°)	d-value (Å)
1	11.51	7.684	11.53	7.671
2	11.76	7.521	11.78	7.508
3	12.30	7.188	12.32	7.180
4	13.59	6.512	13.61	6.503
5	14.02	6.312	14.04	6.304
6	15.34	5.770	15.36	5.765
7	16.22	5.460	16.24	5.455
8	16.96	5.224	16.98	5.219
9	17.48	5.069	17.50	5.065
10	17.92	4.945	17.95	4.939
11	18.67	4.749	18.69	4.745
12	20.48	4.333	20.51	4.328
13	20.85	4.256	20.87	4.254
14	21.69	4.094	21.71	4.091
15	22.53	3.943	22.55	3.941
16	23.10	3.847	23.12	3.845
17	24.50	3.630	24.52	3.628
18	25.23	3.528	25.25	3.525
19	25.65	3.471	25.67	3.468
20	26.21	3.398	26.23	3.396
21	26.92	3.310	26.94	3.308
22	27.80	3.207	27.82	3.205
23	30.46	2.932	30.48	2.931
24	30.68	2.912	30.70	2.910
25	33.92	2.640	33.94	2.639
26	34.92	2.567	34.94	2.567

TABLE 3 — Comparison of the X-ray powder diffraction data of the samples before and after grinding and micronization Conclusion: The crystal forms of the samples had not changed under the conditions of direct grinding and micronization.

		Data obtained after	Data obtained after
	At the beginning	grinding	micronization
	2θ	d-value	2θ	d-value	2θ	d-value
Numbers	(°)	(Å)	(°)	(Å)	(°)	(Å)
1	11.51	7.684	11.50	7.691	11.54	7.664
2	11.76	7.521	11.75	7.527	11.79	7.502
3	12.30	7.188	12.29	7.198	12.33	7.175
4	13.59	6.512	13.58	6.517	13.62	6.498
5	14.02	6.312	14.01	6.318	14.05	6.300
6	15.34	5.770	15.33	5.777	15.37	5.762
7	16.22	5.460	16.21	5.465	16.25	5.452
8	16.96	5.224	16.95	5.228	16.99	5.216
9	17.48	5.069	17.47	5.074	17.51	5.062
10	17.92	4.945	17.91	4.950	17.95	4.939
11	18.67	4.749	18.66	4.753	18.70	4.743
12	20.48	4.333	20.47	4.336	20.51	4.328
13	20.85	4.256	20.84	4.260	20.88	4.252
14	21.69	4.094	21.68	4.097	21.72	4.090
15	22.53	3.943	22.52	3.946	22.56	3.939
16	23.10	3.847	23.09	3.850	23.13	3.843
17	24.50	3.630	24.49	3.633	24.53	3.627
18	25.23	3.528	25.22	3.529	25.26	3.523
19	25.65	3.471	25.64	3.472	25.68	3.467
20	26.21	3.398	26.20	3.399	26.24	3.394
21	26.92	3.310	26.91	3.311	26.95	3.307
22	27.80	3.207	27.79	3.209	27.83	3.204
23	30.46	2.932	30.45	2.934	30.49	2.930
24	30.68	2.912	30.67	2.913	30.71	2.910
25	33.92	2.640	33.91	2.642	33.95	2.639
26	34.92	2.567	34.91	2.569	34.95	2.566

TABLE 5 — Comparison of the data of samples placed under long-term stability conditions Time (months) Conclusion: The samples had good stability under the long-term storage conditions.

Inspection items	0	3	6
Appearance	White powder	White powder	White powder
HPLC identification	Consistent	Consistent	Consistent
Clarity and color of	Clear and	Clear and	Clear and
dimethylsulfoxide	colorless	colorless	colorless
solution
Related	Maximum	0.03	0.04	0.03
substance	unknown
(%)	single
	impurity
	Total	0.12	0.13	0.13
	impurities
Moisture (%)	0.04	0.08	0.08
Particle size	d (0.5) ≤15 μm	d (0.5) ≤15 μm	d (0.5) ≤15 μm
	d (0.9) ≤30 μm	d (0.9) ≤30 μm	d (0.9) ≤30 μm
Content (%)	99.6	100.0	99.7

TABLE 6 — Dissolution data of 20 mg specification products (n = 6) Medium Conclusion: The dissolution results of the tablets prepared from the samples showed that the dissolution rates of the tabletsin 0.1 mol/L HCl solution, acetate buffer pH 4.5, phosphate buffer pH 6.8 and purified water were all more than 85% at 15 minutes.

	Acetate buffer	Phosphate
	0.1 mol/L HCl	Purified water	pH 4.5	buffer pH 6.8
Time	X	RSD	X	RSD	X	RSD	X	RSD
(min)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
10	94	2.8	92	3.4	93	3.4	90	1.7
15	97	2.4	95	3.7	97	2.4	94	1.8
30	99	1.1	95	2.3	99	3.2	95	1.4
45	101	1.2	98	2.1	101	3.7	99	1.0

Claims as granted

5 claims

Classifications

1 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C07D401/12

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

4.2 y

1,534 days filing → grant

Office actions

after a restriction

Responses

no RCE

Examiner

Patricia L Morris

art unit 1625 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 15 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.